Company announces nivolumab plus chemotherapy and nivolumab with ipilimumab demonstrate superior survival benefit in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) in Phase 3 CheckMate -648 trial

Results show statistically significant benefit for primary endpoint of overall survival (OS) in patients whose tumours express PD-L1 and in the all-randomised patient population at the pre-specified interim analysis. Results to be shared at upcoming conference.

Biospace Inc.